Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505890-34-00

Enrollment

Registered

2024-03-05

Start date

2024-06-27

Completion date

Unknown

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal dominant polycystic kidney disease

Brief summary

Relative change from baseline total kidney volume (TKV) to month 18 of treatment (%/year).

Interventions

DRUGJardiance 10 mg film-coated tablets

DRUGPlacebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Relative change from baseline total kidney volume (TKV) to month 18 of treatment (%/year).	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 5, 2026